Journal of cutaneous medicine and surgery · 2015
Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bourcier Marc, Papp Kim Alexander, Gulliver Wayne P, Poulin Yves, Barber Kirk, Poulin-Costello Melanie, Shelton Jennifer
Аннотация
BACKGROUND: Currently, etanercept (ETN) safety and efficacy in patients with moderate to severe plaque psoriasis (PsO) has been reported up to 5 years.
OBJECTIVE: To present a case series of PsO patients receiving continuous ETN therapy for 7 or more years.
METHODS: Physicians collected data retrospectively from 52 patient charts from 5 centres across Canada.
RESULTS: Patients in this case series had PsO an average of 31.5 years. Nearly half of patients also had psoriatic arthritis (24/52). All patients demonstrated sustained improvement in Psoriasis Area and Severity Index (PASI) and percentage of affected body surface area (BSA) following ETN treatment. Of the 52 patients, 33 have been receiving ETN for 10 years or more.
CONCLUSION: The clinical experience described in this case series report suggests maintenance of ETN efficacy in PsO patients who receive therapy for 7 years or more and indicates that patients can be successfully managed with long-term ETN therapy.
OBJECTIVE: To present a case series of PsO patients receiving continuous ETN therapy for 7 or more years.
METHODS: Physicians collected data retrospectively from 52 patient charts from 5 centres across Canada.
RESULTS: Patients in this case series had PsO an average of 31.5 years. Nearly half of patients also had psoriatic arthritis (24/52). All patients demonstrated sustained improvement in Psoriasis Area and Severity Index (PASI) and percentage of affected body surface area (BSA) following ETN treatment. Of the 52 patients, 33 have been receiving ETN for 10 years or more.
CONCLUSION: The clinical experience described in this case series report suggests maintenance of ETN efficacy in PsO patients who receive therapy for 7 years or more and indicates that patients can be successfully managed with long-term ETN therapy.